Pfizer Vyndaqel family — Revenues: decreased by 5.1% to $1.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $1.49B to $1.60B. Over 4 years (FY 2021 to FY 2025), Vyndaqel family — Revenues: shows an upward trend with a 33.4% CAGR.
pfe_segment_vyndaqel_family_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $501.00M | $501.00M | $561.00M | $612.00M | $552.00M | $602.00M | $681.00M | $686.00M | $782.00M | $892.00M | $961.00M | $1.14B | $1.32B | $1.45B | $1.54B | $1.49B | $1.62B | $1.59B | $1.69B | $1.60B |
| QoQ Change | — | +0.0% | +12.0% | +9.1% | -9.8% | +9.1% | +13.1% | +0.7% | +14.0% | +14.1% | +7.7% | +18.3% | +16.4% | +9.4% | +6.7% | -3.8% | +8.7% | -1.5% | +6.1% | -5.1% |
| YoY Change | — | — | — | — | +10.2% | +20.2% | +21.4% | +12.1% | +41.7% | +48.2% | +41.1% | +65.7% | +69.2% | +62.2% | +60.7% | +30.7% | +22.1% | +10.0% | +9.3% | +7.8% |